Aptose Biosciences price target lowered to $15 from $50 at Oppenheimer

Oppenheimer lowered the firm’s price target on Aptose Biosciences to $15 from $50 and keeps an Outperform rating on the shares. The company reported Q2 results and discussed new data from the APTIVATE trial, the analyst tells investors in a research note. In nine evaluable patients who failed prior venetoclax-containing therapy, four achieved complete remissions with the tuspetinib plus venetoclax combo, says the firm. Opco is not sure if these data “are strong enough to entice investors back into the story en masse.” It cut the price target on expected dilution and higher market risk premium.